Advicenne SA (ALDVI) AI Stock Analysis

• Market Cap: €17.99M
• Dividend Yield: N/A
• Average Volume (3M): 39.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.25
• Revenue Growth: 69.03%
• EPS Growth: 20.69%
• Country: FR
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 14,219,619
• 10 Day Avg. Volume: 31,050
• 30 Day Avg. Volume: 39,589
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €1.00
• Price Target Upside: -21.26% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: €1.50 ▲(18.11% Upside)

Advicenne SA's overall stock score is primarily impacted by its financial performance, which is hindered by significant profitability and financial stability challenges. While technical analysis shows some short-term bullish signals, the long-term trend remains bearish. The negative P/E ratio and lack of dividend yield further weigh down the valuation score.

Advicenne SA Business Overview & Revenue Model

Company Description

Advicenne SA (ALDVI) is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare diseases, particularly those affecting pediatric patients. The company focuses on addressing unmet medical needs through its lead product, ADV7103, which is designed to treat primary hyperoxaluria type 1, a rare genetic disorder. Advicenne operates primarily in the healthcare sector, leveraging its expertise in drug development to enhance treatment options for patients with specific metabolic disorders.

How the Company Makes Money

Advicenne generates revenue primarily through the commercialization of its pharmaceutical products, notably ADV7103. The company may also receive funding through partnerships with larger pharmaceutical firms, research grants, and governmental support aimed at rare disease treatments. Additional revenue streams could include licensing agreements for its proprietary technologies and potential milestone payments from collaborations. The success of its products in clinical trials and subsequent market approvals significantly influences its revenue potential, as does the expansion of its product pipeline into new therapeutic areas.

Advicenne SA Financial Statement Overview

Summary

Advicenne SA demonstrates strong revenue growth but faces significant challenges in profitability, financial stability, and cash flow generation. The negative margins and equity position highlight operational and financial risks. The company needs to address these issues to improve its financial health and sustainability.

Income Statement

Advicenne SA shows a significant revenue growth rate of 49.21% in the latest year, indicating strong top-line expansion. However, the company struggles with profitability, as evidenced by negative gross profit and net profit margins. The EBIT and EBITDA margins are also negative, reflecting operational challenges. Overall, while revenue growth is a positive sign, the lack of profitability is a major concern.

Balance Sheet

The balance sheet reveals a precarious financial position with negative stockholders' equity, indicating potential solvency issues. The debt-to-equity ratio is not meaningful due to negative equity, and the return on equity is also negative. The equity ratio is negative, highlighting a high-risk financial structure. Overall, the balance sheet reflects significant financial instability.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a significant decline in free cash flow growth. The operating cash flow to net income ratio is zero, indicating cash flow challenges. The free cash flow to net income ratio is also zero, suggesting inefficiencies in converting income to cash. Overall, the cash flow situation is concerning, with limited cash generation capabilities.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.97M	4.46M	2.40M	2.69M	2.06M
Gross Profit	-359.00K	1.43M	1.28M	1.72M	1.18M
EBITDA	1.30M	-6.24M	-9.87M	-12.04M	-14.05M
Net Income	-6.46M	-7.03M	-11.47M	-12.43M	-14.85M
Balance Sheet
Total Assets	9.51M	12.41M	14.26M	18.88M	24.00M
Cash, Cash Equivalents and Short-Term Investments	3.25M	5.25M	8.32M	12.69M	16.77M
Total Debt	18.19M	19.86M	18.75M	12.54M	13.80M
Total Liabilities	28.58M	24.38M	24.88M	18.57M	20.73M
Stockholders Equity	-19.07M	-11.97M	-10.62M	309.00K	3.27M
Cash Flow
Free Cash Flow	-853.00K	-7.27M	-9.26M	-12.82M	-12.27M
Operating Cash Flow	-762.00K	-5.99M	-9.15M	-12.53M	-11.69M
Investing Cash Flow	-108.00K	-1.32M	-2.00K	-451.00K	-694.00K
Financing Cash Flow	-1.13M	4.23M	4.78M	8.85M	12.53M

Advicenne SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.27
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALDVI, the sentiment is Negative. The current price of 1.27 is below the 20-day moving average (MA) of 1.27, above the 50-day MA of 1.25, and below the 200-day MA of 1.64, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 49.19 is Neutral, neither overbought nor oversold. The STOCH value of 26.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALDVI.

Advicenne SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALDVI	49 Neutral	€17.99M	―		―	69.03%	20.69%
SIGHT	47 Neutral	23.17M	-1.03	52.01%	―	-50.00%	73.05%
ALVAL	46 Neutral	18.81M	-1.26	-96.69%	―	0.00%	0.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%